Jan 19: Mumbai-based pharma firm Lupin Ltd on Friday announced the launch of its Doxycycline Hyclate Tablet USP, 100 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier.
“Lupin’s Doxycycline Hyclate Tablet USP, 100 mg is the AB rated generic equivalent of Pfizer Inc.’s Vibra-Tabs, 100 mg. It is indicated in the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne,” the company said in a statement.
According to IMS MAT November 2017 data, Doxycycline Hyclate Tablet USP, 100 mg had annual sales of approximately $ 144 million in the US.
Lupin shares were trading in red at Rs 918.35, down 0.01% from the previous closing of Rs 918.40, on BSE at 2.01 pm today.